Abstract 327P
Background
Sentinel lymph node biopsy (SLNB) has been widely used to assess axillary staging. In clinical practice, it is crucial to define sentinel lymph node (SLN) and determine whether the detected nodes are SLNs during the process of SLNB. It is important to consider whether currently existing consensus on SLNB method which is dual-tracer technique may lead to the excessive and unnecessary removal of negative nodes. In addition, no uniform measurable and objective index has been established to define intra-operation palpable nodes, the excision of which may increase the random detection of SLN. The purpose of this study was to optimize the specific method of SLNB.
Methods
To propose an optimal cut-off value for “radioisotope+bule dye” dual-tracer method, the detailed information of (BC) patients who had no clinical node involvement and underwent SLNB from November 2010 to February 2021 was prospectively collected in the breast surgery department of West China Hospital. We analyzed the site and size, radioactivity, the status of blue dye and the pathological results of each node detected of each patients.
Results
A total of 4985 lymph nodes from 1595 BC patients were identified. Only 11.57% (577/4985) SLNs were defined as pathologically positive, resulting in 88.43% (4408/4985) negative nodes removed excessively. By gradually increasing the threshold of radioisotope count in comparison to the hottest SLN, we found that when elevating the cut-off value from 10% to approximately 60%, 17.3% of lymph nodes were spared removal, among which only 0.88% were missed positive SLNs. Raising the optimal cutoff value of radioisotopes to 60% and exempting palpable nodes at the same time could reduce the number of nodes detected by 30.81% with only 1.75% missed positive SLNs. Additionally, multivariate analysis in our study showed that larger tumor size and higher clinical N stage was significantly positively associated with SLN metastasis.
Conclusions
Raising the optimal cut-off value of radioisotope to 60% and exempting palpable nodes may be considered as a potential alternative method to avoid removing excessive negative nodes in SLNB.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Q. Lv.
Funding
West China Hospital, Sichuan University.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
313P - Intrinsic subtypes in a cohort of early breast cancer patients
Presenter: Theresa Bracht
Session: Poster session 02
314P - Concordance of somatic variants between circulating tumor DNA and tissue in patients with breast cancer
Presenter: Kangsu Shin
Session: Poster session 02
315P - Multinational survey study assessing genetic testing and counselling among patients (pts) with breast cancer (MAGENTA): Results on perceptions on testing
Presenter: Sarah Powell
Session: Poster session 02
316P - Comprehensive characterization of the HER2-enriched intrinsic molecular subtype in ER-positive HER2-negative breast cancer
Presenter: Lennart Hohmann
Session: Poster session 02
317P - Awareness of genomic testing among patients with breast cancer in Europe
Presenter: Antonella Cardone
Session: Poster session 02
318P - Evaluation of novel diagnostic kits using the semi-dry dot-blot method combined for detecting metastases in sentinel lymph nodes of patients with breast cancer: A multi-center prospective study
Presenter: Ryota Otsubo
Session: Poster session 02
319P - The impact of low HER2 expression on clinical significances and outcomes in patients with HER2-negative early breast cancer
Presenter: Yumiko Koi
Session: Poster session 02
320P - Clinical and pathological characteristics of breast cancers switching from early luminal-like to metastatic triple-negative phenotype
Presenter: Mariia Ivanova
Session: Poster session 02
321P - Non-BRCA variants in hereditary breast and ovarian cancer patients in the northern Mexico population
Presenter: Dione Aguilar
Session: Poster session 02
322P - Clinicopathological characteristics and genomic profiling of pure mucinous breast cancer
Presenter: Shusen Wang
Session: Poster session 02